Theratechnologies Inc.
2310 Alfred-Nobel Boulevard
Saint-Laurent
Quebec
H4S 2A4
Canada
Tel: 514-336-7800
Fax: 514-336-7242
Website: http://www.theratech.com/
Email: webinfo@theratech.com.
326 articles about Theratechnologies Inc.
-
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
12/13/2023
Theratechnologies Inc. today announced that the United States Food and Drug Administration (FDA) has approved the company’s Labelling Prior Approval Supplement to include a 2000-mg intravenous (IV) push loading dose for Trogarzo® (ibalizumab-uiyk).
-
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award
11/24/2023
Theratechnologies Inc. today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from the CQDM (formerly known as the Québec Consortium for Drug Discovery) and the Association for the Development of Research and Innovation of Québec (ADRIQ).
-
Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
10/31/2023
Theratechnologies Inc. announced that it has closed its previously announced public offering of 12,500,000 common shares of the Company at a public offering price of US$1.00 per Common Share.
-
Theratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private Placement
10/26/2023
Theratechnologies Inc. announced that it has priced its previously announced public offering of 12,500,000 common shares of the Company at a public offering price of US$1.00 per Common Share.
-
Theratechnologies Announces Operational Update
10/24/2023
Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced further changes to its operations that will see a tapering of R&D activities, which necessitates a reduction of up to 25 positions.
-
Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV
10/19/2023
Theratechnologies Inc. today shared data demonstrating the cost-effectiveness of ibalizumab, a monoclonal antibody antiretroviral therapy (ART) commercialized in the U.S. under the trade name Trogarzo®, as an addition to optimized background regimens (OBR) in heavily treatment-experienced (HTE) people with HIV.
-
Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon
10/16/2023
Theratechnologies Inc. announced that it has finalized all documentation giving effect to the amendments to certain of the terms and conditions of its credit agreement dated July 20, 2022, as amended from time to time, with certain funds and accounts for which Marathon Asset Management, L.P. acts as investment manager.
-
Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
10/13/2023
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today presented data in a poster session at ID Week 2023 in Boston, Mass., demonstrating that treatment with tesamorelin significantly reduced visceral adipose tissue (VAT) and hepatic fat fraction (HFF, a measure of liver fat) in people with HIV treated with integrase inhibitor (INSTI) based regimens.
-
Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study
10/13/2023
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced results from a study evaluating an intramuscular (IM) method of administration for Trogarzo® (ibalizumab-uiyk), a monoclonal antibody antiretroviral therapy (ART) for the treatment of heavily treatment-experienced adults with multidrug-resistant (MDR) HIV-1 infection failing their current antiretroviral regimen.
-
Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
10/12/2023
Theratechnologies Inc. today announced dosing of the first participant in Part 3 of its Phase 1 clinical trial of sudocetaxel zendusortide in patients with advanced ovarian cancer.
-
Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA
10/4/2023
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021.
-
Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
9/26/2023
Theratechnologies Inc. today reported business highlights and financial results for the third quarter and first nine months of fiscal year 2023, ended August 31, 2023. All figures are in U.S. dollars unless otherwise stated.
-
Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review
9/25/2023
Theratechnologies Inc. today announced that the Company has filed a supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin to the U.S. Food and Drug Administration (FDA) for review.
-
Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility
9/25/2023
Theratechnologies Inc. today announced that it has reached an agreement in principle to amend some of the terms and conditions of its credit agreement dated July 20, 2022, as amended from time to time (the “Loan Facility”), with certain funds and accounts for which Marathon Asset Management, L.P. acts as investment manager (collectively, “Marathon”).
-
Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023
9/20/2023
Theratechnologies Inc. today announced that Mr. Paul Lévesque, President and Chief Executive Officer, will participate in a panel presentation at the Cantor Fitzgerald Global Healthcare Conference 2023 being held September 26-28 in New York City.
-
Theratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business Update
9/18/2023
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX)today announced the Company will report financial results and provide a business update for its third quarter ended August 31, 2023, on Tuesday, September 26 at 8:30 a.m. EDT.
-
Theratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference
9/7/2023
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) will present at the H.C. Wainwright 25th Annual Global Investment Conference, to be held virtually and in person on September 11-13, 2023, in New York City at the Lotte New York Palace Hotel.
-
Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights
9/5/2023
Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced that the Company expects to report positive adjusted EBITDA1 for its third quarter ended August 31, 2023.
-
Theratechnologies Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide
8/30/2023
Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced that all five of the U.S.-based clinical sites participating in the conduct of the Phase 1 clinical trial of the Company’s lead investigational peptide drug conjugate, sudocetaxel zendusortide, are now activated to screen, enroll and dose advanced ovarian cancer patients.
-
Theratechnologies Announces 1-for-4 Reverse Stock Split
7/20/2023
Theratechnologies Inc. announced that its Board of Directors approved a consolidation of the issued and outstanding common shares of the Company’s share capital on the basis of one post- consolidation share for each four pre-consolidation shares issued and outstanding.